Association of apolipoprotein E ϵ2 and vasculopathy in cerebral amyloid angiopathy

Objective: Hemorrhage related to cerebral amyloid angiopathy (CAA) appears to occur through a multistep pathway that includes deposition of β-amyloid in cerebral vessels and specific vasculopathic changes in the amyloid-laden vessels, such as cracking of the vessel wall. Recent reports suggest a positive association between CAA-related hemorrhage and both the apolipoprotein E (APOE) ϵ4 allele and, unexpectedly, the APOE ϵ2 allele. Unlike APOE ϵ4, APOE ϵ2 does not appear to act through increased β-amyloid deposition. We therefore sought to determine whether it might specifically accelerate the second step in this pathway, that is, development of the vasculopathic changes that lead to hemorrhage. Methods: To determine the role of APOE in development of vasculopathic changes, we compared APOE genotypes in two groups of postmortem brains: 52 brains with complete amyloid replacement of vessel walls but without vasculopathic changes, and 23 brains with complete amyloid replacement of vessels with the accompanying changes of cracking of the vessel wall and paravascular leaking of blood. Results: Frequency of APOE ϵ2 was significantly greater in the group with vasculopathy (0.09) than the group without (0.01, p = 0.03). The groups did not differ in mean age or extent of neuritic plaques. Analysis of a clinical series of patients with CAA-related hemorrhage confirmed an overrepresentation of APOE ϵ2 as well as an association between this allele and earlier age of first hemorrhage. Conclusions: These data suggest that APOE ϵ2 and ϵ4 might promote CAA-related hemorrhage through separate mechanisms: ϵ4 by enhancing amyloid deposition and ϵ2 by causing amyloid-laden vessels to undergo the vasculopathic changes that lead to rupture.

[1]  B. Hyman,et al.  Cerebral amyloid angiopathy and apolipoprotein E: Bad news for the good allele? , 1997, Annals of neurology.

[2]  D. Graham,et al.  High frequency of apolipoprotein E ϵ2 Allele in hemorrhage due to cerebral amyloid angiopathy , 1997, Annals of neurology.

[3]  R. Terry.  The pathology of Alzheimer's disease: Numbers count , 1997, Annals of neurology.

[4]  Bradley T. Hyman,et al.  Apolipoprotein E ε4 Is Associated With the Presence and Earlier Onset of Hemorrhage in Cerebral Amyloid Angiopathy , 1996 .

[5]  L. Thal,et al.  The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant , 1996, Neurology.

[6]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[7]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[8]  K Kontula,et al.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.

[9]  W. V. Van Nostrand,et al.  Amyloid β-Protein Aggregation Nullifies Its Pathologic Properties in Cultured Cerebrovascular Smooth Muscle Cells (*) , 1995, The Journal of Biological Chemistry.

[10]  B. Hyman,et al.  Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy , 1995 .

[11]  M. Levitt,et al.  A Comparison of Symptoms after the Consumption of Milk or Lactose-Hydrolyzed Milk by People with Self-Reported Severe Lactose Intolerance , 1995 .

[12]  J. Haines,et al.  Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease , 1995, Neurology.

[13]  T. Bird.  Apolipoprotein E genotyping in the diagnosis of alzheimer's disease: A cautionary view , 1995, Annals of neurology.

[14]  S. Younkin,et al.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). , 1995, The Journal of biological chemistry.

[15]  P. Lansbury,et al.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. MacDonald,et al.  An Improved Approach to Prepare Human Brains for Research , 1995, Journal of neuropathology and experimental neurology.

[17]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Putterman.  Compromise sought over germplasm access , 1994, Nature.

[19]  K. Jobst,et al.  Protective effect of apo epsilon 2 in Alzheimer's disease. Oxford Project to Investigate Memory and Ageing (OPTIMA) , 1994, Lancet.

[20]  S. Kennedy.  When is a disease occupational? , 1994, The Lancet.

[21]  N. Craddock,et al.  Protection against Alzheimer's disease with apoE ∈2 , 1994, The Lancet.

[22]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[23]  H. Vinters,et al.  Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. , 1994, Ultrastructural pathology.

[24]  D. Schaid,et al.  Apolipoprotein E: risk factor for Alzheimer disease. , 1994, American journal of human genetics.

[25]  C. Ryan.  Oligosaccharide signals: from plant defense to parasite offense. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Miyatake,et al.  Computer‐Assisted Three‐Dimensional Image Analysis of Cerebral Amyloid Angiopathy , 1993, Stroke.

[27]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Hugh S. Markus,et al.  Differentiation Between Different Pathological Cerebral Embolic Materials Using Transcranial Doppler in an In Vitro Model , 1993, Stroke.

[29]  R. Penn,et al.  Neurosurgical horizons in Parkinson's disease , 1993, Neurology.

[30]  J. Vonsattel,et al.  Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study , 1991, Annals of neurology.

[31]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[32]  R. Rosenberg.  Autosomal dominant cerebellar phenotypes , 1990, Neurology.

[33]  G. Glenner,et al.  Differences Between Vascular and Plaque Core Amyloid in Alzheimer's Disease , 1988, Journal of neurochemistry.

[34]  H. Vinters.  Cerebral amyloid angiopathy. A critical review. , 1987, Stroke.

[35]  T. Mandybur.  Cerebral Amyloid Angiopathy: The Vascular Pathology and Complications , 1986, Journal of neuropathology and experimental neurology.

[36]  L D Lunsford,et al.  Factors that predict the bleeding risk of cerebral arteriovenous malformations. , 1996, Stroke.

[37]  J. Ma,et al.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. , 1994, Nature.

[38]  T. Iwatsubo,et al.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.

[39]  B. Scheithauer,et al.  Ultrastructure of multiple sclerosis. , 1994, Ultrastructural pathology.

[40]  D. Deregt,et al.  ELISA reliable for detection of antibodies to BHV1. , 1993, The Canadian veterinary journal = La revue veterinaire canadienne.